1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

  • February 2016
  • -
  • La Merie Publishing
  • -
  • 42 pages

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of February 2016. The report covers live attenuated or whole virus vaccines, recombinant subunit and DNA-based vaccines for prophylaxis of Dengue fever as well as therapeutic antibodies and other antivirals directed against Dengue Virus. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Dengue virus (DENV) is a mosquito-borne flavivirus that infects at least 390 million people per year. It is estimated that nearly half the world's population is at risk for dengue infection. The primary mosquito vector for dengue, Aedes aegypti, continues to spread widely and into new habitats due to increased urbanization and climate change.

Dengue vaccines could have beneficial individual-level effects by reducing the probability of infection given exposure to an infected mosquito. In addition, with increasing vaccine coverage in a population, vaccines could reduce the overall transmission in the entire community, even to unvaccinated people, and thus have indirect or herd effects. The first Dengue vaccine only recently has been approved in three countries and several more vaccine candidates are in the pipeline.

Therapeutic antibodies and other antiviral agents might help in the post-exposure prophylaxis and treatment of Dengue virus-infected indivivuals. Several candidates are in the development pipeline. Preclinical studies of a candidate antibody have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its continued development as a single administration for the treatment of dengue virus infection.

The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines, Antibodies and Antivirals. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Dengue Virus Vaccines, Antibodies and Antivirals

Competitor Analysis: Dengue Virus Vaccines, Antibodies andamp; Antivirals


Table of contents


1) Dengue Virus Vaccines:



  • Live Attenuated or Inactivated Whole-Virus Dengue Virus Vaccines

  • Recombinant Subunit Dengue Virus Vaccines

  • DNA-based Dengue Virus Vaccines

  • Others


2) Dengue Virus Therapeutic Antibodies


3) Dengue Virus Antivirals


4) Corporate Dengue Virus Vaccines, Antibodies andamp; Antivirals Randamp;D Pipeline

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Human Vaccines Market: Scope and Methodology This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.